Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Research & Development (2024 - 2025)

Kairos Pharma's Research & Development history spans 2 years, with the latest figure at $496000.0 for Q2 2025.

  • For Q2 2025, Research & Development rose 687.3% year-over-year to $496000.0; the TTM value through Jun 2025 reached $1.2 million, changed N/A, while the annual FY2025 figure was $2.1 million, 415.7% up from the prior year.
  • Research & Development reached $496000.0 in Q2 2025 per KAPA's latest filing, up from $493000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $496000.0 in Q2 2025 to a low of $14000.0 in Q3 2024.